JPRN-UMIN000011859已完成2 期
A phase II study of maintenance therapy with WT1 peptide-based cancer vaccine following the first-line therapy for advanced-stage ovarian cancer - WT1Ov
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Residual diseases after surgical and chemotherapy 2) Received intra-peritoneum chemotherapy 3) Active other cancers except for carcinoma in situ treated completely 4) Received Immunosuppresive agents actively at registration 5) Received Growth factor, including G-CSF, Epo, TPO, within 14 days before registration 6) Received other tested agents within 28 days before registration 7) Received WT1 vaccine 8) Past history of Myeloproliferative diseases, MSD 9) Past history of pulmonary fibrosis, interstitial pneumonitis 10) Past history of autoimmune diseases, including collagen diseases 11) Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 12) active infectious diseases 13) Past history of HIV, HBV, and HCV infections 14) Grade 3 or severer Neutopatic complications 15) Hypersensitivity to some drugs 16) Pregnancy / lactation 17) Severe Psychological Problems 18) Other severe problems unsuitable for this study
研究者
相似试验
进行中（未招募）
1 期
Clinical trial of combination chemotherapy with anti-angiogenic agent aflibercept in patients with advanced colorectal cancerEUCTR2013-002567-26-GRHellenic Cooperative Oncology Group73
已完成
1 期
A phase I study of combination therapy with WT1 peptide-pulsed dendritic cells and gemcitabine for advanced pancreatic and biliary tumorspancreatic and biliary tumorsJPRN-UMIN000004063Department of Internal medicine, Division of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine35
尚未招募
不适用
A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancerNeoplasmsKCT0008619ational Cancer Center138
进行中（未招募）
1 期
Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer.MedDRA version: 21.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancerEUCTR2017-000987-14-ITAZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO130
尚未招募
1 期
A study in blood cancer patients to check the effect of two oral drugs in maintaining the status of the patient disease free. The medicines that will be given are azacytidine and pomalidomide.CTRI/2023/09/057552Tata Memorial Centre